The biobanks of the Valencian Biobank Network move towards excellence with accreditation a... 28/11/2023 Healthcare Access to innovation All biobanks in the RVB currently have a quality management system certified according to the ISO 9001:2015. Partners
The CrisBio technology from Cocoon opens new doors to the production of recombinant protei... 27/11/2023 Healthcare Access to innovation The CrisBio® platform uses a totally different protein expression system, since it uses the pupae of the Trichoplusia NI... Partners - COCOON BIOSCIENCE S.L.
BCN HEALTH publishes a study evaluating the hospital incidence and medical costs of polycy... 27/11/2023 Healthcare Access to innovation Partners - BCN Health
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatme... 23/11/2023 Healthcare Access to innovation Partners - Almirall
Celtarys Research, a startup developing innovative chemical biology solutions, participate... 21/11/2023 Healthcare Access to innovation Partners - Celtarys Research
BCN HEALTH has presented several communications at the EASL and AASLD congresses evaluatin... 20/11/2023 Healthcare Access to innovation BCN HEALTH has participated in the EASL and AASLD congresses with several communications that have reported on the... Partners - BCN Health
Science and Innovation, the Pending Subject of Spain and a Weak Point in the Progress towa... 10/11/2023 Healthcare Access to innovation Climate change Agrifood Industrial biotechnology Financing Talento Spain needs a clear regulatory framework and support for the biotechnological industry with long-term investments... AseBio
Science and Innovation, the Pending Subject of Spain and a Weak Point in the Progress towa... 10/11/2023 Beyond the direct impact of biotechnology on human health and the planet, investment in science and biotechnology has a... AseBio
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases 07/11/2023 Healthcare Access to innovation Lead candidate KYN-5356, a first-in-class small Molecule KAT-II inhibitor advancing toward the clinic for cognitive... Partners - Ysios Capital Partners
ORYZON announces Last Patient Last Visit in its Phase IIb PORTICO study for Borderline Per... 07/11/2023 Healthcare Access to innovation Innovative drugs Multiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement. Partners - Oryzon Genomics
